Found: 8
Select item for more details and to access through your institution.
The novel anti-cancer fluoropyrimidine NUC-3373 is a potent inhibitor of thymidylate synthase and an effective DNA-damaging agent.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2023, v. 91, n. 5, p. 401, doi. 10.1007/s00280-023-04528-5
- By:
- Publication type:
- Article
Plasma endothelin-1 may predict bevacizumab-induced proteinuria in patients with colorectal cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2023, v. 91, n. 5, p. 427, doi. 10.1007/s00280-023-04532-9
- By:
- Publication type:
- Article
A PK-PD model linking biomarker dynamics to progression-free survival in patients treated with everolimus and sorafenib combination therapy, EVESOR phase I trial.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2023, v. 91, n. 5, p. 413, doi. 10.1007/s00280-023-04520-z
- By:
- Publication type:
- Article
Synergistic action of lactoferrin in enhancing the safety and effectiveness of docetaxel treatment against prostate cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2023, v. 91, n. 5, p. 375, doi. 10.1007/s00280-023-04524-9
- By:
- Publication type:
- Article
A phase IV study evaluating QT interval, pharmacokinetics, and safety following fractionated dosing of gemtuzumab ozogamicin in patients with relapsed/refractory CD33-positive acute myeloid leukemia.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2023, v. 91, n. 5, p. 441, doi. 10.1007/s00280-023-04516-9
- By:
- Publication type:
- Article
Cardioprotective potential of mitochondria-targeted antioxidant, mito-TEMPO, in 5-fluorouracil-induced cardiotoxicity.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2023, v. 91, n. 5, p. 389, doi. 10.1007/s00280-023-04529-4
- By:
- Publication type:
- Article
Precision fluoropyrimidines dosing in a compound heterozygous variant carrier of the DPYD gene: a case report.
- Published in:
- 2023
- By:
- Publication type:
- Case Study
Clinical results of the EVESOR trial, a multiparameter phase I trial of everolimus and sorafenib combination in solid tumors.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2023, v. 91, n. 5, p. 361, doi. 10.1007/s00280-023-04508-9
- By:
- Publication type:
- Article